Synmosa Biopharma (4114) — Cash Flow Quality Index
Synmosa Biopharma (4114) has a Cash Flow Quality Index of 0.98x as of December 2025. Operating cash flow of NT$185.72 Million is below net income of NT$189.22 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Synmosa Biopharma (4114) cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Synmosa Biopharma Cash Flow Quality Index (2015–2025)
Historical Cash Flow Quality Index for Synmosa Biopharma across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check how aggressively does Synmosa Biopharma reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Synmosa Biopharma (2015–2025)
Year-by-year earnings quality comparison for Synmosa Biopharma. For live market cap and the full company financial profile, see 4114 stock market capitalisation.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.50x | NT$411.57 Million | NT$821.85 Million | ▼ -56.1% |
| 2024 | 1.14x | NT$780.62 Million | NT$684.68 Million | ▲ +24.2% |
| 2023 | 0.92x | NT$511.93 Million | NT$557.82 Million | ▲ +16.4% |
| 2022 | 0.79x | NT$630.25 Million | NT$799.09 Million | ▼ -46.1% |
| 2021 | 1.46x | NT$444.29 Million | NT$303.86 Million | ▲ +266.8% |
| 2020 | 0.40x | NT$254.40 Million | NT$638.11 Million | ▲ +141.8% |
| 2019 | -0.95x | NT$-44.88 Million | NT$47.09 Million | ▼ -2667.5% |
| 2018 | 0.04x | NT$16.00 Million | NT$430.90 Million | ▲ +103.4% |
| 2017 | -1.11x | NT$-5.19 Million | NT$4.69 Million | ▼ -178.1% |
| 2016 | 1.42x | NT$236.48 Million | NT$166.65 Million | ▲ +89.6% |
| 2015 | 0.75x | NT$23.60 Million | NT$31.54 Million | — |